glp-1 agonists marketing strategies 2025 The effect on MedTech GLP-1 Receptor Agonist Market Size,

Holland, MD, MS, lead author, total joint arthroplasty surgeon at Campbell Clinic Orthopaedics and a faculty instructor at the University of Tennessee Health Science Center in Memphis

By 2024, an estimated 12% of American adults reported taking a GLP-1 medication for diabetes, weight loss, or heart disease, according to data from the Kaiser Family Foundation

While pharmacotherapies for treatment of obesity prior to GLP-1RAs have had limited impact on cardiovascular outcomes, bariatric surgical procedures have shown long-standing, durable outcomes [7]

Different drugs performed better in different areas, but all 15 GLP-1RAs they analyzed were very successful in lowering blood glucose and achieving weight loss

Evers said the Pharmacare program in the majority of provinces, including in Atlantic Canada, does not cover the cost of GLP-1 drugs for obesity because it has not yet been recognized as a chronic disease